We also observed that a majority of transcripts that contain EZH2 binding sites in the promoter region that are differentially expressed between prostate cancer tissue and the benign-adjacent tissues have decreased expression in the prostate cancer tissue (Fig. 2b). Here, EZH2 is linked to prostate cancer.